Aptar Digital Health Partners with Enable Injections, Inc. to Advance enFuse® Companion Digital Solution
Aptar Digital Health, a global leader in digital healthcare solutions focused on improving patient experiences, has announced a strategic partnership with Enable Injections, Inc., an innovative company specializing in advanced drug delivery systems. This collaboration designates Aptar Digital Health as the preferred digital health partner for Enable’s enFuse® On-Body Delivery System.
The partnership reflects a shared vision between the two organizations: to elevate the standard of care by combining cutting-edge drug delivery technology with intelligent digital solutions. Together, they aim to create a comprehensive ecosystem that supports patients, caregivers, and healthcare providers throughout the treatment journey.
At the heart of this collaboration is the development of a companion digital solution designed specifically for the enFuse® system. This solution will play a critical role in guiding users through the injection process while also fostering engagement before, during, and after treatment administration.
A Digital Companion for the enFuse® System
The enFuse® On-Body Delivery System is designed to administer large-volume biologics in a convenient and patient-friendly manner. Recognizing the growing complexity of therapies and the challenges associated with self-administration, Aptar Digital Health is developing a digital companion that complements the device’s functionality.
This digital solution is intended to provide patients and caregivers with intuitive, step-by-step guidance throughout the injection process. By simplifying complex procedures and offering real-time support, the platform aims to reduce anxiety, improve confidence, and ensure proper usage of the device.
In addition to procedural guidance, the solution is expected to include a range of features that enhance overall treatment management. These may include onboarding tools, educational resources, and personalized support mechanisms that help users better understand their therapy and stay engaged over time.
Key Features Designed to Support Adherence
A major focus of the partnership is improving patient adherence—a critical factor in achieving optimal treatment outcomes, particularly for chronic conditions requiring long-term therapy. The companion digital solution is being designed with several key features aimed at addressing adherence challenges:
- Treatment Data Recording: Patients will be able to log and track their treatment sessions, creating a detailed history that can be reviewed by both patients and healthcare providers.
- Onboarding and Training Modules: Interactive training resources will help patients and caregivers become familiar with the enFuse® system, ensuring correct usage from the start.
- Injection Guidance: Step-by-step instructions and reminders will guide users through each stage of the injection process, minimizing errors and enhancing confidence.
- Patient-Reported Outcomes (PROs): The platform will allow users to report symptoms, side effects, and overall treatment experiences, providing valuable insights into real-world therapy performance.
- Symptom T
- racking: Continuous monitoring of symptoms will help patients better understand their condition and communicate effectively with healthcare professionals.
These features collectively aim to empower patients by giving them greater control over their treatment while also providing healthcare providers with actionable insights.
Scalable Architecture for Broad Application
One of the defining characteristics of the companion digital solution is its flexible and scalable architecture. Designed to adapt to various therapeutic areas and program requirements, the platform can be deployed alongside the enFuse® system across different stages of the drug development lifecycle.
From early-stage clinical trials to full-scale commercial launches, the solution is built to evolve in alignment with pharmaceutical partners’ strategies. This adaptability ensures that the platform remains relevant and effective as therapies progress from development to real-world use.
Pharmaceutical companies will be able to integrate digital components into their programs based on specific needs, whether for clinical data collection, patient engagement, or post-market support. This modular approach enhances the value of the enFuse® system by extending its capabilities beyond drug delivery alone.
Enabling Data-Driven Insights
A critical advantage of the digital solution lies in its ability to capture and analyze data. By combining device-generated information with patient-reported outcomes, the platform will create a comprehensive dataset that reflects real-world treatment usage.
This data will be securely stored and accessible through advanced analytics dashboards. These dashboards are designed to generate actionable insights that can support:
- Clinical Development: Providing real-world evidence to inform trial design and optimization.
- Launch Readiness: Helping pharmaceutical companies prepare for successful product introductions.
- Post-Market Monitoring: Offering ongoing insights into patient behavior and treatment effectiveness.
The integration of real-time data collection and analytics represents a significant step forward in personalized healthcare. It allows stakeholders to make more informed decisions and continuously improve treatment strategies based on actual patient experiences.
Enhancing Patient Engagement Beyond Injection
Both companies emphasize that the collaboration goes beyond improving the mechanics of drug delivery. Instead, it focuses on enhancing the entire treatment experience.
Michael D. Hooven, Chairman and CEO of Enable Injections, highlighted the broader impact of the partnership, noting that it aims to extend support beyond the moment of injection. By combining innovative delivery technology with digital tools, the collaboration seeks to keep patients actively engaged in their therapy.
This continuous engagement is particularly important for patients managing chronic conditions, where long-term adherence can be challenging. By providing ongoing support, reminders, and feedback, the digital solution helps patients stay on track and maintain consistency in their treatment.
Addressing Challenges of Biologic Therapies
The partnership comes at a time when large-volume biologic therapies are becoming increasingly prevalent in the treatment of complex chronic diseases. These therapies often require precise administration and sustained adherence to achieve desired outcomes.
Damien McKeon, SVP of Strategic Partnerships at Aptar Digital Health, emphasized the importance of digital solutions in addressing these challenges. He noted that treatment tracking and patient engagement tools can play a crucial role in overcoming common barriers associated with self-administration.
By integrating digital support with the enFuse® system, the collaboration aims to simplify the treatment process and reduce the burden on patients. This approach not only improves adherence but also enhances overall patient satisfaction and outcomes.
Supporting Healthcare Providers and Caregivers
While the primary focus is on patients, the digital solution also offers significant benefits for healthcare providers and caregivers. By providing access to detailed treatment data and patient-reported outcomes, the platform enables more informed and proactive care.
Healthcare professionals can use these insights to:
- Monitor patient progress more effectively
- Identify potential issues early
- Adjust treatment plans based on real-world data
Caregivers, on the other hand, gain access to tools that help them support patients more confidently, ensuring that treatments are administered correctly and consistently.
A Step Toward the Future of Connected Healthcare
The partnership between Aptar Digital Health and Enable Injections represents a broader trend toward connected healthcare ecosystems. By integrating medical devices with digital platforms, companies are creating solutions that go beyond traditional treatment methods.
This approach aligns with the growing demand for personalized, data-driven healthcare experiences. Patients today expect more than just effective therapies—they seek tools that help them manage their health proactively and conveniently.
The enFuse® companion digital solution is a clear example of this shift. By combining advanced drug delivery with intelligent digital support, it sets a new standard for patient-centric care.
The collaboration between Aptar Digital Health and Enable Injections marks a significant milestone in the evolution of drug delivery and digital health integration. By developing a companion digital solution for the enFuse® system, the two companies are addressing critical challenges in patient adherence, engagement, and data utilization.
Through its comprehensive feature set, scalable design, and focus on real-world insights, the platform has the potential to transform how patients experience and manage their treatments. At the same time, it provides pharmaceutical companies and healthcare providers with valuable tools to optimize outcomes and drive innovation.
As healthcare continues to move toward more connected and personalized models, partnerships like this one will play a crucial role in shaping the future of patient care.
adherence challenges associated with self-administration.”
About Aptar Digital Health
Aptar Pharma’s Digital Health division is part of AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, including dosing and protection technologies, and consumer product dispensing. Aptar Digital Health creates end-to-end solutions to enhance patient experiences every day, leveraging a holistic ecosystem of digital interventions. Amplified by an industry-leading portfolio of products and solutions, Aptar Digital Health’s offering combines mobile and web apps, Software-as-Medical-Device, connected drug delivery systems, advanced data analysis services, and patient onboarding and training solutions to actively empower patients and create a positive treatment journey. Headquartered in Crystal Lake, Illinois, Aptar employs 14,000 dedicated people across 20 countries
About Enable Injections
Cincinnati-based Enable Injections is a global healthcare innovation company committed to improving the patient treatment experience through the development and manufacturing of the enFuse® on-body drug delivery system. An innovative wearable technology, the enFuse® system is designed to deliver large volumes of pharmaceutical and biologic therapeutics via subcutaneous administration, with the aim of improving convenience, supporting improved outcomes, and advancing healthcare system economics.
Enable is currently working with a number of pharmaceutical partners to conduct clinical trials and plan for the joint commercial launch of their therapies in combination with the enFuse® technology.
